Recursion Pharmaceuticals Inc. (RXRX) News
Filter RXRX News Items
RXRX News Results
|Loading, please wait...
RXRX News Highlights
- For RXRX, its 30 day story count is now at 10.
- Over the past 16 days, the trend for RXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about RXRX are DRUG, DEC and RARE.
Latest RXRX News From Around the Web
Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
In this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US. Life expectancy of a newborn […]
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries w
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.
These two biotech stocks hold enormous potential.
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on December 13, 2023.
Wood is moving away from fintech and Internet names like COIN stock.
Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently forecasts about 23% upside potential in the next 12 months. Plus, Recursion’s strategic partnership with some big names, including NVIDIA (NASDAQ:NVDA), to revolutionize AI in drug discovery has Wall Street optimistic about its long-term potential. Recursion’s commitment to tackling rare diseases will drive i
9 micro/small cap AI stocks are still in bubble mode advancing 14.8%, on average, last week. In comparison, the Global X Artificial Intelligence & Technology ETF was only up 0.5% and the iShares Semiconductor ETF was only up 1.6%.
In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023.